evipedia.ai
← Back

DMAE for Health & Longevity

Evidence Review created on 09/28/2026 using AI4L / Opus 5.5

Also known as: Dimethylaminoethanol, Deanol, Dimethylethanolamine, 2-dimethylaminoethanol, 2-(dimethylamino)ethanol, DMEA, Deaner, Deanol Acetamidobenzoate, DMAE Bitartrate, Deanol Bitartrate, Deanol Aceglumate, DMAE Pyroglutamate

Motivation

Dimethylaminoethanol (DMAE, also called deanol) is a small molecule closely related to choline, a nutrient the body uses to build cell membranes and a chemical messenger involved in memory and attention. It is sold as an oral supplement for mental focus and mood, and as an ingredient in skin creams marketed for firmness. Its appeal for health-minded adults lies in the idea that a simple, inexpensive compound might support both the aging brain and aging skin.

Interest dates back to the 1950s, when a form of the compound was sold as a prescription medication for children with learning and behavior problems, until it left the market in 1983. In the 1970s, a lifespan study in elderly mice drew the attention of aging researchers, and a closely related drug was tested in Europe for age-related memory decline.

This review examines what human and animal studies report about DMAE taken orally or applied to the skin, to test whether the long-standing claims for the aging brain and skin are supported by evidence. It covers the proposed effects on the brain, skin and lifespan, the side effects and safety questions, and how the compound is used in practice.

Benefits - Risks - Protocol - Conclusion

This section lists overview articles and narrative reviews that discuss DMAE or its closely related ester centrophenoxine in depth.

No relevant DMAE content was found from Rhonda Patrick, Peter Attia, Andrew Huberman or Chris Kresser; site searches and web searches returned no episodes or articles discussing DMAE or centrophenoxine.

Grokipedia

Dimethylethanolamine

Mostly covers industrial chemistry and hazards, with sections on the withdrawn prescription use and pharmacology; some statements, such as its summary of the 1975 deanol attention trial, conflict with the primary source.

Examine

DMAE

Brief summary of proposed brain and skin effects; its database grades only one human trial (241 participants, early Alzheimer’s disease), showing no effect on cognitive decline.

ConsumerLab

No dedicated ConsumerLab article on DMAE exists. DMAE is mentioned only within ConsumerLab’s broader answer page on supplements for attention problems, which does not review DMAE products.

Systematic Reviews

This section lists systematic reviews and meta-analyses that include DMAE (deanol); all concern its use for drug-induced movement disorders.

No systematic review or meta-analysis addresses DMAE for cognition, skin, mood or lifespan, so those claimed effects are unrepresented here.

Mechanism of Action

DMAE is choline missing one methyl group. Choline is a nutrient used to make acetylcholine (a nerve-signaling chemical central to memory, attention and muscle control) and phosphatidylcholine (the main fat in cell membranes). Three explanations compete:

  • Cholinergic precursor: the original theory holds that DMAE crosses into the brain and is converted to choline, raising acetylcholine. Rat neurons can incorporate DMAE into choline-containing lipids (Andriamampandry et al., 1989).
  • Choline competitor: DMAE competes with choline for the blood-brain barrier (the filter between blood and brain) transporter, raising blood choline while limiting its brain entry (Millington et al., 1978). A 2019 rodent study found no conversion to choline and low brain levels (Shipkowski et al., 2019).
  • Membrane and free-radical effects: DMAE scavenges hydroxyl radicals (highly reactive oxygen molecules) in test tubes, the basis of the membrane hypothesis of aging (Nagy & Floyd, 1984). On skin, concentrated DMAE swells cells with fluid-filled vacuoles, which may explain rapid “firming” (Morissette et al., 2007).

Pharmacology: absorbed orally; in rodents 16–69% is excreted in urine, tissue retention is moderate and brain concentrations low without accumulation. Main metabolites are DMAE N-oxide and N,N-dimethylglycine (Shipkowski et al., 2019); no cytochrome P450 (CYP, liver drug-metabolizing enzyme) pathway is documented. Human half-life is uncharacterized; urinary N-oxide peaks 2–5 hours after a dose (Krug et al., 2023). DMAE binds no specific receptor.

Historical Context & Evolution

DMAE was introduced in the late 1950s by Riker Laboratories as the prescription drug Deaner (deanol acetamidobenzoate), a mild “psychic energizer” for children with learning and behavior problems, then called minimal brain dysfunction. After the 1962 US law requiring proof of efficacy, the manufacturer declined to fund new trials, and Deaner left the market in 1983. This was a regulatory decision, not a finding of harm or inefficacy; a 1975 double-blind trial had reported improvement similar to methylphenidate (Lewis & Young, 1975).

In the 1970s deanol was tested for tardive dyskinesia, where a meta-analysis of controlled trials found no advantage over placebo (Soares & McGrath, 1999). The same decade brought longevity interest: Richard Hochschild reported longer survival in old mice given deanol (Hochschild, 1973), while centrophenoxine, a DMAE ester developed in France, was studied for lipofuscin (age pigment) removal and dementia, notably by Imre Zs-Nagy. Later animal studies did not reproduce some effects (Stenbäck et al., 1988; Andrews & Brizzee, 1986).

From the late 1990s, dermatologist Nicholas Perricone popularized topical DMAE for skin firming, supported by company-funded trials (narrative review: Grossman, 2005). A 242-person trial of DMAE pyroglutamate for early Alzheimer’s disease, funded by its manufacturer Pierre Fabre, found no cognitive benefit (Dubois et al., 2012). Since 2019, National Toxicology Program studies have questioned the choline-precursor theory (Shipkowski et al., 2019) and found no neural tube defects (spine and brain malformations) in rats, but equivocal evidence of other developmental toxicity (National Toxicology Program prenatal study). The evidence remains open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no DMAE outcome with a clinical endpoint or validated surrogate has been replicated with a positive result in more than one controlled human trial.

Medium 🟩 🟩

Attention and Behavior in Children With Learning Problems ⭕️ Not Central to Health & Longevity

In a double-blind trial of 74 children with learning and behavior problems, 3 months of deanol 500 mg/day improved several behavior ratings and standardized mental-ability tests versus placebo, in a pattern similar to methylphenidate, a prescription stimulant for ADHD (attention-deficit/hyperactivity disorder) (Lewis & Young, 1975). A later review judged the effect probably small (Hurt et al., 2011). This bears on childhood attention problems, not adult health or longevity.

Magnitude: Improvement on several behavior and mental-ability measures after 3 months at 500 mg/day, similar in pattern to methylphenidate 40 mg/day; the trial abstract reports no effect-size figure.

Fatigue and Low Energy

In a randomized add-on trial in 60 psychiatric patients with asthenia (persistent fatigue and weakness), deanol aceglumate (a DMAE salt) 1,000 mg/day for 30 days reduced asthenic and cognitive complaints more than standard treatment alone (Smulevich et al., 2017). The abstract describes no placebo, so expectation effects cannot be excluded. Evidence rests on this single Russian trial.

Magnitude: Direction only: significantly greater reduction in asthenic and cognitive complaints over 30 days versus standard treatment alone; the literature reports no outcome figure.

Tension-Type Headache in Children ⭕️ Not Central to Health & Longevity

In a blinded, placebo-controlled trial of 40 children and adolescents aged 9–16, deanol aceglumate taken for 2 months as prevention reduced the frequency, duration and intensity of tension-type headaches and eased fatigue (Shipilova et al., 2016). Evidence rests on this single small Russian trial. This bears on childhood headache, not adult health or longevity.

Magnitude: Direction only: fewer, shorter and milder headaches over 2 months versus placebo; the literature reports no outcome figure.

Alcohol Withdrawal Symptoms ⭕️ Not Central to Health & Longevity

In an open, randomized multicenter trial of 90 patients, adding deanol aceglumate to standard treatment reduced alcohol withdrawal and fatigue scores more than standard treatment alone (Agibalova et al., 2018). The open design allows expectation effects. This bears on addiction treatment, not healthy aging.

Magnitude: Direction only: significantly greater reduction on the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, a withdrawal severity scale) and a fatigue inventory throughout treatment; the literature reports no outcome figure.

Low 🟩

Memory and Thinking in Aging ⚠️ Conflicted

Centrophenoxine improved memory in elders (Marcer & Hopkins, 1977; Pék et al., 1989). DMAE eased drug-induced forgetfulness in young men in a manufacturer (Pierre Fabre) study (Blin et al., 2009), but failed in older adults (Marsh & Linnoila, 1979) and Alzheimer’s (Dubois et al., 2012). Net: no DMAE clinical benefit.

Magnitude: Centrophenoxine 2 g/day in moderate dementia: memory improved in 48% versus 28% on placebo over 8 weeks; DMAE pyroglutamate 1,500 mg/day in early Alzheimer’s disease: no significant difference over 24 weeks.

Mood in Older Adults

In an open 4-week study of 14 older adults with dementia, deanol up to 1,800 mg/day eased depression, irritability and anxiety but not memory (Ferris et al., 1977). A DMAE-containing vitamin-mineral product improved mood versus placebo, but DMAE’s share is unknown (Dimpfel et al., 2003). Evidence is uncontrolled or indirect.

Magnitude: 10 of 14 older adults with dementia were rated globally improved at 4 weeks in the uncontrolled study, mainly through reduced depression, irritability and anxiety.

Skin Firmness and Fine Lines ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A 3% DMAE gel increased a firmness measure in a randomized split-face trial (Uhoda et al., 2002); an independent study found no change in skin mechanics (Tadini & Campos, 2009). This bears on appearance. Net: short-term firming is plausible, durable benefit unproven.

Magnitude: Direction only: faster shear-wave speed (firmer skin) on the treated side of 30 volunteers and fewer forehead and eye-area fine lines after 16 weeks in a company trial summarized in a narrative review (Grossman, 2005); published reports give no outcome figure.

Involuntary Movement Disorders ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Early open reports suggested deanol eased tardive dyskinesia, but controlled trials and meta-analyses found no benefit over placebo (Soares & McGrath, 1999); it also failed in Huntington’s chorea (an inherited disorder causing involuntary movements) (Caraceni et al., 1978). This bears on movement disorders. Net: controlled evidence shows no benefit.

Magnitude: Pooled across older cholinergic drugs including deanol, the RR (risk ratio, the relative likelihood of an outcome) of no improvement was 0.84, 95% CI (confidence interval, the range of plausible values) 0.68–1.04, not statistically significant (Tammenmaa et al., 2004).

Exercise Capacity

In a crossover trial of 50 male physical-education teachers, 6 weeks of a ginseng, DMAE, vitamin and mineral product increased treadmill workload and maximal oxygen uptake (peak aerobic capacity) versus placebo (Pieralisi et al., 1991). Ginseng cannot be separated from DMAE, so evidence is indirect.

Magnitude: Direction only: higher total workload and maximal oxygen uptake, with lower lactate (a by-product of intense muscle work) and heart rate at equal workloads; the abstract reports no effect-size figure.

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

Deanol lengthened remaining survival of old mice (Hochschild, 1973); lifelong DMAE did not in another strain (Stenbäck et al., 1988). Animal data only. Net: inconsistent and unreplicated.

Clearance of Age Pigment ⚠️ Conflicted

Lipofuscin (waste pigment accumulating in aging cells) fell with centrophenoxine in old mice (Nandy, 1978) but not in aged monkeys (Andrews & Brizzee, 1986). Net: unconfirmed; animal data only.

Free-Radical Scavenging

DMAE neutralizes hydroxyl radicals in test-tube experiments (Nagy & Floyd, 1984). The basis is mechanistic only; no human outcome data exist.

Vivid or Lucid Dreaming ⭕️ Not Central to Health & Longevity

A hypothesis paper proposed DMAE to induce lucid dreams, in which dreamers know they are dreaming (Sergio, 1988). The basis is anecdotal; it bears on sleep experience only.

Benefit-Modifying Factors

  • Genetic polymorphisms: no pharmacogenetic data exist. Variants in PEMT (phosphatidylethanolamine N-methyltransferase, the liver enzyme that makes choline) raise dietary choline needs and could theoretically alter response to a choline analog; this is untested.
  • Baseline biomarkers and choline status: low dietary choline intake (few eggs, meat or fish) might plausibly change response, but no study has stratified DMAE outcomes by plasma choline or any other biomarker.
  • Sex: no sex-specific benefit data exist; most adult trials pooled men and women, and the exercise trial enrolled only men.
  • Pre-existing conditions: responses were absent in DMAE trials for Alzheimer’s disease, Huntington’s chorea and tardive dyskinesia; benefit signals came from children with attention problems, psychiatric patients with fatigue and, in small studies, older adults with dementia (mood with deanol, memory with centrophenoxine).
  • Age: older adults contributed most cognitive data; DMAE itself showed no benefit and more side effects in older adults with Alzheimer’s disease, whereas centrophenoxine showed modest memory signals in both healthy and demented older adults.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Drowsiness, Confusion, Insomnia and Headache

Central nervous system effects are the most consistent adverse events. In a double-blind Alzheimer’s trial, deanol caused drowsiness, slowing and increased confusion (Fisman et al., 1981); a meta-analysis found significantly more adverse events with deanol than placebo (Soares & McGrath, 1999); headache was among the most frequent events with DMAE pyroglutamate (Dubois et al., 2012). A drug monograph also lists insomnia, excitation, vivid dreams, constipation, itching and involuntary face and mouth movements (RxList deanol monograph). Effects are dose-related and reversible on stopping.

Magnitude: 6 of 13 (46%) deanol-treated patients with moderate-to-severe Alzheimer’s withdrew within 5 weeks; adverse events occurred in 43.5% versus 29.6% on placebo with DMAE pyroglutamate 1,500 mg/day.

Medium 🟥 🟥

Blood Pressure Elevation

Mild blood pressure rises were among the reasons for withdrawal in a controlled trial in older adults with Alzheimer’s disease (Fisman et al., 1981). Evidence comes from one small trial and drug-reference warnings.

Magnitude: Direction only: mild increases reported in treated patients with Alzheimer’s disease; the literature reports no outcome figure.

Seizures and Serious Cardiac Events

Among people taking DMAE pyroglutamate, one grand mal seizure (generalized convulsive seizure), one cardiorespiratory arrest and one fatal cardiac failure occurred; causality was not excluded (Dubois et al., 2012). A drug monograph advises against use in grand mal seizure disorders (RxList deanol monograph). Data are sparse and uncontrolled for causality.

Magnitude: 3 serious adverse events among roughly 121 treated older adults over 24 weeks; investigators could not exclude a relation to the drug.

Low 🟥

Mood Destabilization and Worsening Psychosis

In an uncontrolled series, high-dose deanol triggered depression or hypomania (mild mania with elevated energy and reduced need for sleep), mostly in people with prior mood disorders (Casey, 1979). In a placebo-controlled trial, schizophrenia symptoms showed a non-significant trend toward worsening (de Montigny et al., 1979). Changes reversed after stopping.

Magnitude: 8 of 38 (21%) patients on high doses developed mood changes (5 depression, 3 hypomania); 7 of the 8 had prior mood symptoms.

Eye Irritation and Vision Disturbance From Vapor or Liquid

Concentrated liquid DMAE is corrosive. Workers exposed to DMAE and a related amine vapor reported blurry, halo and blue-grey vision, with corneal clouding (Page et al., 2003). Symptoms tracked total amine exposure, not DMAE alone. Relevant only to handling the liquid free base, not capsules.

Magnitude: 89% of line workers with higher total-amine exposure reported blurry vision at work versus 12.5% of other workers; DMAE levels were higher in the lower-symptom group, so the figure mainly reflects the related amine.

Speculative 🟨

Neural Tube Defects in Pregnancy ⚠️ Conflicted

DMAE, by blocking choline uptake, caused neural tube defects (spine and brain malformations) in cultured mouse embryos (Fisher et al., 2001); pregnant rats showed none (National Toxicology Program prenatal study). Net: unresolved; no human data.

Skin Cell Vacuolization and Fibroblast Damage

Concentrated DMAE swells skin cells with vacuoles (Morissette et al., 2007) and reduces fibroblast (collagen-making cell) growth in culture (Gragnani et al., 2007). Basis is laboratory only.

Reduced Brain Choline Supply ⚠️ Conflicted

DMAE competed with choline for brain entry in rats (Millington et al., 1978); a later rodent study found no effect on choline handling (Shipkowski et al., 2019). Net: unresolved animal data.

Risk-Modifying Factors

  • Genetic polymorphisms: no pharmacogenetic studies exist. Carriers of PEMT variants with higher choline needs could theoretically be more sensitive to choline competition; this is untested.
  • Baseline biomarkers: elevated baseline blood pressure increases the relevance of reported pressure rises; low choline intake could, in theory, magnify choline competition.
  • Sex: women who are or may become pregnant carry the unresolved neural tube concern; no other sex differences in side effects are documented.
  • Pre-existing conditions: epilepsy, bipolar disorder, depression, schizophrenia and uncontrolled hypertension raise risk of seizures, mood switches, psychosis and blood pressure rises.
  • Age: older adults, especially with dementia, had high withdrawal rates from drowsiness and confusion; serious cardiac events occurred in an older trial population.

Key Interactions & Contraindications

  • Anticholinergic drugs (acetylcholine blockers: oxybutynin, benztropine, amitriptyline, scopolamine): caution; DMAE may oppose their effect or theirs may cancel DMAE’s intended action. Prescriber review before combining is the usual safeguard.
  • Cholinesterase inhibitors (drugs slowing acetylcholine breakdown: donepezil, rivastigmine, galantamine): caution; additive cholinergic effects may increase nausea, slow heart rate or confusion. Symptom and pulse monitoring applies if combined.
  • Antipsychotics (psychosis medications: haloperidol, risperidone, olanzapine): contraindicated in schizophrenia; deanol trended toward worsening psychotic symptoms in a controlled trial (de Montigny et al., 1979).
  • Anticonvulsants (seizure medications: valproate, levetiracetam, lamotrigine): contraindicated in epilepsy; a drug monograph advises against deanol in grand mal (tonic-clonic) seizure disorders (RxList deanol monograph), implying possible lowering of seizure threshold and breakthrough seizures.
  • Antidepressants and mood stabilizers (depression and bipolar disorder medications: sertraline, bupropion, lithium): caution; deanol has triggered depression and hypomania. Weekly mood monitoring during the first month is typical.
  • Antihypertensives (blood pressure medications: lisinopril, amlodipine, losartan): monitor; blood pressure rises may reduce control. Home blood pressure checks during the first 4 weeks detect this.
  • Over-the-counter sedating antihistamines (allergy and sleep-aid medications: diphenhydramine, doxylamine, meclizine): caution; anticholinergic action opposes DMAE and may worsen confusion in older adults. Routine combination is generally avoided.
  • Over-the-counter decongestants (nasal-congestion relievers: pseudoephedrine, phenylephrine): caution; additive blood pressure and stimulation effects. The combination is generally avoided in hypertension.
  • Cholinergic supplements (citicoline, alpha-GPC (a choline source), huperzine A, centrophenoxine): caution; additive cholinergic effects cause headache, muscle tension or insomnia. Centrophenoxine releases DMAE and duplicates the dose. Protocols typically use one cholinergic agent at a time.
  • Stimulants (caffeine, other nootropic (cognition-enhancing) stimulants): monitor; additive overstimulation and insomnia. Limiting caffeine and avoiding late-day dosing reduce this.
  • Other interventions (topical retinoids (vitamin A-derived skin agents), alpha-hydroxy acids (exfoliating fruit acids)): caution; stacking with DMAE creams may increase skin irritation. Introducing one product at a time limits this.

Populations who should avoid DMAE:

  • Pregnant or breastfeeding women and women trying to conceive
  • People with epilepsy, particularly generalized tonic-clonic (grand mal) seizures
  • People with bipolar disorder or a history of hypomania
  • People with schizophrenia or other psychotic disorders
  • People with uncontrolled hypertension (above 160/100 mm Hg)
  • People with moderate-to-severe dementia (drowsiness and confusion risk)
  • Children, outside medical supervision
  • Athletes subject to anti-doping rules using centrophenoxine, which is prohibited in competition

Risk Mitigation Strategies

  • Low starting dose: protocols typically begin with 100–150 mg DMAE bitartrate daily for 1–2 weeks before increasing, reducing headache, insomnia and drowsiness.
  • Studied dose ceiling: oral intake is typically kept at or below about 500 mg DMAE base daily; drowsiness, confusion and mood effects appeared mostly at 1,000–2,000 mg daily.
  • Morning or early-afternoon dosing: the last dose is usually taken before 2 pm, preventing insomnia and vivid dreams.
  • Blood pressure checks: home blood pressure is measured at baseline and weekly for 4 weeks, with a systolic rise above 10 mm Hg as the usual stopping point, preventing untreated pressure elevation.
  • Mood screening: a PHQ-9 (Patient Health Questionnaire-9, a depression questionnaire) at baseline and 4 weeks, with stopping on any new low mood or unusual euphoria, guards against depressive or hypomanic episodes.
  • Pregnancy exclusion: stopping DMAE at least 1 month before trying to conceive avoids the unresolved neural tube defect risk.
  • Single cholinergic agent: not stacking DMAE with centrophenoxine, citicoline or alpha-GPC prevents duplicate dosing and additive cholinergic side effects.
  • Intermittent topical use: skin gains persisted through a 2-week pause in a company trial (narrative review: Grossman, 2005), so periodic breaks reduce cumulative exposure to the cell swelling and fibroblast damage seen with concentrated DMAE in laboratory studies.
  • No liquid free base: capsules or finished cosmetics, rather than industrial liquid DMAE, prevent corrosive skin and eye injury.

Therapeutic Protocol

  • Standard oral protocol: DMAE bitartrate 150 mg daily (about 55 mg DMAE base), the capsule Life Extension sells; its magazine cites 50–130 mg as common; trials used 500–1,800 mg deanol daily (Lewis & Young, 1975; Ferris et al., 1977).
  • Centrophenoxine alternative: 600–1,200 mg daily in divided doses; 2 g daily in a dementia trial (Pék et al., 1989). Popularized by Imre Zs-Nagy’s membrane hypothesis of aging.
  • Topical protocol: 3% DMAE gel or cream applied once daily to the face for 16 weeks, popularized by dermatologist Nicholas Perricone, whose company sells DMAE creams.
  • Choline-donor alternatives: some practitioners prefer citicoline or alpha-GPC as better-characterized choline sources; this is a competing approach, not a DMAE protocol.
  • Time of day: morning, with or after breakfast; a second dose no later than early afternoon, because stimulation and insomnia are the commonest complaints.
  • Half-life: human plasma half-life is not characterized; urinary metabolite peaks 2–5 hours after dosing, consistent with short action.
  • Single vs split dosing: split doses (2–3 times daily) were used in historical trials; single morning doses suit lower intakes below about 300 mg base.
  • Genetic polymorphisms: no genotype-guided dosing exists; PEMT variant carriers with high choline needs might keep dietary choline adequate while trialing DMAE.
  • Sex: no sex-specific dosing; protocols for women of reproductive age include confirming no current or planned pregnancy.
  • Age: protocols for adults over 70 typically start at the low end (100–150 mg bitartrate) given higher confusion and withdrawal rates in older trial populations.
  • Baseline biomarkers: normal blood pressure and a low baseline depression score favor tolerability; elevated values argue for lower doses or avoidance.
  • Pre-existing conditions: epilepsy, bipolar disorder, psychosis and uncontrolled hypertension exclude use; mild cognitive complaints are the most studied adult indication.

Discontinuation & Cycling

  • Short-term trial: DMAE is used as a time-limited trial of 4–12 weeks, continued only if a clear, tracked benefit appears; no data support lifelong use.
  • Withdrawal effects: none documented after stopping oral or topical DMAE; side effects such as insomnia and mood changes reversed on discontinuation.
  • Tapering: not required; abrupt stopping is acceptable. Halving the dose for a week is optional for those who noticed stimulation effects.
  • Cycling: no evidence shows cycling maintains efficacy; some users pause periodically (e.g., 5 days on, 2 off) to reassess benefit, an untested practice.
  • Topical regimen: in a company trial summarized in a narrative review, skin improvements did not regress during a 2-week pause, so intermittent application is plausible (Grossman, 2005).

Sourcing and Quality

  • Salt versus base: DMAE bitartrate contains about 37% DMAE by weight; labels may state salt or base weight, so 350 mg bitartrate supplies roughly 130 mg DMAE.
  • Formulations: capsules (bitartrate), deanol aceglumate (a prescription drug in Russia), DMAE pyroglutamate (an investigational drug tested by Pierre Fabre, not marketed), centrophenoxine (DMAE ester, prescription in some countries) and topical creams, typically 1–3% DMAE.
  • Third-party testing: NSF (NSF International, a product-certification body) or USP (United States Pharmacopeia) verification, or a published certificate of analysis, documents identity and purity; few DMAE products carry such certification.
  • Reputable brands: widely distributed supplement brands include Life Extension, NOW Foods and Source Naturals; topical DMAE products are sold under Perricone MD and other cosmetic labels.
  • Avoid industrial material: liquid DMAE sold as a chemical reagent is corrosive and not food grade; it is not intended for ingestion or undiluted skin application.

Practical Considerations

  • Time to effect: topical firming appears within hours; wrinkle changes took 16 weeks in a company trial (narrative review: Grossman, 2005). Oral mood effects appeared by 3–4 weeks (Ferris et al., 1977); child attention was assessed at 3 months (Lewis & Young, 1975).
  • Common pitfalls: confusing salt with base dose, stacking with centrophenoxine or other choline sources, dosing late in the day, and extrapolating mouse lifespan data to humans.
  • Regulatory status: sold as a dietary supplement in the United States without approval for any indication; Deaner was withdrawn in 1983 after efficacy requirements tightened.
  • Anti-doping: centrophenoxine is prohibited in competition by WADA (World Anti-Doping Agency); DMAE intake raises the same urinary marker, which could complicate testing.
  • Cost and access: oral DMAE is inexpensive and widely available; centrophenoxine requires import or prescription in some countries.

Interaction with Foundational Habits

  • Sleep: direct, blunting when dosed late: insomnia and vivid dreams are common complaints, likely from cholinergic stimulation. Morning dosing is the usual practice; lucid-dream use relies only on anecdote (Sergio, 1988).
  • Nutrition: indirect: DMAE is a choline analog, so dietary choline from eggs, fish, meat and legumes remains the main choline source. Small amounts of DMAE occur in fish such as sardines and anchovies. Taking capsules with breakfast may reduce stomach upset.
  • Exercise: none shown for DMAE alone: the only exercise trial used a ginseng combination product, so any potentiating effect cannot be attributed to DMAE (Pieralisi et al., 1991). No evidence of blunted training adaptation exists.
  • Stress management: indirect, potentiating for mood in some: an open study reported less anxiety and irritability (Ferris et al., 1977), while high doses triggered mood swings in susceptible people. No cortisol data exist; established stress practices carry stronger evidence than DMAE.

Monitoring Protocol & Defining Success

Before starting DMAE, baseline testing includes seated blood pressure and resting heart rate, a PHQ-9 depression score, a pregnancy test for women who could conceive, and a baseline cognitive score such as the MoCA (Montreal Cognitive Assessment, a 30-point screening test) or a repeatable computerized test. Liver enzymes are optional as a general safety check, and a two-week sleep diary establishes a reference for insomnia.

Ongoing monitoring follows this cadence: home blood pressure weekly for 4 weeks, then monthly; PHQ-9 and sleep review at 2 and 4 weeks; cognitive retesting at 8–12 weeks using the same instrument; then every 6 months while continuing. Success is defined in advance as a measurable improvement in the chosen cognitive, mood or skin measure without blood pressure, mood or sleep deterioration. Absent a clear gain by 12 weeks, discontinuation is the usual choice.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure Below 120/80 mm Hg Detect DMAE-related rises Conventional target below 130/80 mm Hg; seated, after 5 minutes rest, same time of day
Resting heart rate 50–70 beats per minute Detect cholinergic slowing or stimulation Conventional range 60–100; measure on waking; pair with blood pressure
PHQ-9 depression score 0–4 Detect mood destabilization PHQ-9 = Patient Health Questionnaire-9; 5–9 is conventionally “mild”; repeat at 2 and 4 weeks
Cognitive score (MoCA or computerized test) MoCA 26–30; no established target for computerized tests, track change from own baseline Define cognitive success MoCA = Montreal Cognitive Assessment; use the same version and time of day; practice effects inflate early retests
ALT (liver enzyme) Below 25 U/L General liver safety ALT = alanine aminotransferase; conventional upper limit about 40–55 U/L; fasting not required; pair with AST (aspartate aminotransferase)
Pregnancy test (hCG) Negative Exclude pregnancy hCG = human chorionic gonadotropin; for women who could conceive; repeat if a period is missed

Qualitative markers:

  • Mental energy and alertness through the afternoon
  • Sleep onset time and dream intensity
  • Mood stability, irritability and motivation
  • Word-finding and short-term memory in daily tasks
  • Skin firmness and fine-line appearance in standardized photos (topical use)
  • Headache, jaw or neck muscle tension

Emerging Research

  • Topical DMAE oleate trial: a single-arm study of 30 adults aged 40–55 applying DMAE oleate nightly for 12 weeks, measuring wrinkle volume and skin firmness; completed December 2025, results not posted (NCT07255560).
  • Multi-ingredient skin serum: an 8-week, triple-blind, placebo-controlled trial in 44 women testing a serum with 2% DMAE, GABA (gamma-aminobutyric acid, a calming brain messenger), cysteamine and bakuchiol for wrinkles and brightness; completed 2025, results not posted; DMAE’s own contribution will be inseparable (NCT07477288).
  • Centrophenoxine in liver-related brain dysfunction: a 300-participant randomized study of meclofenoxate (another name for centrophenoxine) with coenzyme Q10 for hepatic encephalopathy (confusion caused by liver failure); status unknown (NCT03961087).
  • Challenge to the choline-precursor theory: National Toxicology Program disposition work found DMAE is not converted to choline and reaches the brain poorly in rodents, weakening the core cognitive rationale (Shipkowski et al., 2019).
  • Pregnancy safety: rat prenatal studies of DMAE bitartrate up to 1,000 mg/kg/day found no brain malformations but equivocal evidence of other developmental toxicity (a missing artery, short ribs), easing but not resolving embryo-culture concerns (National Toxicology Program prenatal study).
  • Open-label cosmetic data: a 12-week study of a DMAE and retinol serum reported improved submental (under-chin) contour in 13 women; uncontrolled design limits interpretation (Selavdurairaj et al., 2026).
  • Anti-doping detection: urinary deanol-N-oxide testing after DMAE or centrophenoxine use may clarify exposure and how the human body absorbs and clears DMAE (Krug et al., 2023).
  • Unaddressed gaps: no registered trial tests oral DMAE for cognition, healthspan or lifespan in healthy older adults, and no human pregnancy data exist.

Conclusion

DMAE is a small, inexpensive relative of the nutrient choline, sold as a supplement for focus and mood and used in creams for skin firmness. For health-minded adults, its appeal rests on an old idea that it feeds the brain’s memory chemistry and protects aging cells.

The human evidence is thin and mostly decades old. A small benefit on attention in children with learning problems, and less fatigue, childhood tension headache and alcohol withdrawal symptoms in single small trials, each have some controlled support, and applied to the skin it may produce a short-term firming effect. Signals for memory, mood and exercise are mixed, uncontrolled, or come from products where other ingredients cannot be separated out. The largest modern memory study found no benefit, and studies in movement disorders were negative. The lifespan and age-pigment findings come only from animals and have not held up consistently.

On the risk side, drowsiness, confusion, headache and poor sleep are the most consistent problems, with mood swings in people prone to them and rare serious events in older adults with early memory loss. A laboratory signal for birth defects remains unresolved, and newer animal work questions whether the compound even supplies the brain with choline.

Much of the favorable material comes from sellers of supplements and skin products, and the largest memory study was paid for by its maker. Overall, the evidence gives little support for DMAE as a longevity tool, with modest, uncertain effects and real, if mostly mild, side effects.

Top - Benefits - Risks - Protocol